Alto Neuroscience is a Mountain View, CA–based clinical-stage biopharmaceutical company focused on precision psychiatry therapies that pair digital biomarkers with novel CNS drugs. Its lead candidate, ALTO-207—a fixed-dose combination of pramipexole and ondansetron—hit primary and secondary endpoints in a 32-patient Phase 2a study for treatment-resistant depression and is slated to enter Phase 2b by mid-2026 and Phase 3 in early 2027. The firm also advances ALTO-101, which recently secured FDA Fast Track status for cognitive impairment associated with schizophrenia. Alto’s platform employs electroencephalography and cognitive testing to tailor treatments to individual patients. The company carries a market capitalization of about $164.6 million and reports a strong liquidity profile, with a current ratio of 18.43 and more cash than debt, though it is experiencing rapid cash burn. The newly raised capital should extend its runway and fund upcoming clinical milestones.

Total raised

$230M

Funding rounds

6

Latest round

Equity

Latest activity

Oct 2025